Suono Bio

Suono Bio is a biotechnology startup founded in 2017, headquartered in the United States. The company is on a mission to revolutionize targeted gastrointestinal treatments through its proprietary drug delivery platform. Unlike traditional methods, Suono Bio's approach enables localized delivery of various therapies without the need for encapsulation. This breakthrough in drug delivery has the potential to significantly enhance the effectiveness of treatments for challenging diseases. The company recently secured a Series A investment on 29 March 2021, with participation from prominent investors including Axil Capital, Gutbrain Ventures, Mizuho Securities Principal Investment, PBJ Capital, and Taiwania Capital Management Corporation. This funding is expected to propel Suono Bio's innovative advancements and further establish its position in the biotechnology and healthcare industries. Suono Bio's commitment to pioneering localized therapeutic delivery has the potential to reshape the landscape of medical treatments, offering promising prospects for both the company and its investors.